Your fact-checks will appear here
Organization
Available regulatory and manufacturer materials describe Prevnar 20 (PCV20) as a single-dose adult vaccine that provides "lasting protection" against 20 pneumococcal serotypes and is recommended by AC...
For the 2025–26 U.S. flu season, federal agencies recommend using only single‑dose flu vaccine formulations that are free of the preservative thimerosal; most flu doses already supplied in single‑dose...
The removal of the mercury‑based preservative thimerosal from routine U.S. childhood vaccines began as a precautionary policy action in 1999 and was largely completed for childhood immunizations by 20...
Regulatory agencies and multiple studies since 2021 have linked a very small number of neurological and immune-mediated conditions to the Janssen/Johnson & Johnson (J&J) adenoviral‑vector COVID‑19 vac...
Data from national and international public‑health bodies show COVID‑19 vaccines reduce severe outcomes and deaths, especially in older adults: ACIP/CDC presentations found the 2024–25 vaccines “reduc...
Health authorities kept the core public-health message for 2025–26: everyone aged ≥6 months should get an updated flu vaccine, and the 2025–26 U.S. vaccines were reformulated as trivalent to match cir...
Available reporting and official guidance do not describe the Janssen (Johnson & Johnson) COVID-19 vaccine as a substance the body “expels” on a defined timetable; rather, it is an intramuscular viral...
A mercury-containing called (also spelled thiomersal) has been removed from most routine childhood vaccines since the early 2000s, but until recently it remained in a subset of multi-dose influenza va...
There are no widely reported, direct drug–drug interactions between COVID‑19 booster vaccines and routine medications; public health agencies and major health outlets instead emphasize safety monitori...
Major insurer groups have pledged to keep covering and other ‑recommended vaccines without patient cost‑sharing through the end of 2026, even as federal advisory guidance and authorizations narrowed e...
The currently recommends a single dose of an for all adults age 75 years and older, and for adults ages 50–74 who are at increased risk for ; earlier guidance and professional groups also noted recomm...
Available reporting and guidance through 2025 shows common COVID-19 vaccine effects are short-lived (injection-site pain, fever, aches) and that large-scale monitoring finds no widespread, previously ...
Available sources show major health authorities do not recommend ivermectin to prevent or treat COVID‑19 and that research has produced mixed, largely negative or low‑quality signals for its effective...
(thiomersal) remains used primarily as a preservative in multi‑dose vials of influenza (flu) vaccines worldwide, while routine childhood vaccines in high‑income countries have been reformulated to be ...
Available sources show that thimerosal — a mercury-containing preservative used historically in multi-dose vaccine vials — was largely phased out of hepatitis B vaccine formulations in the United Stat...
US immunization guidance has shifted in 2025 from blanket, population-level directives toward more “individual-based decision‑making” for some vaccines: the CDC updated its schedules in October to app...
Booster doses of COVID-19 vaccines produce , with most symptoms resolving in 1–3 days; serious events remain rare but vary by age, sex, vaccine type, and dosing interval . Population surveillance and ...
The evidence collected during and after large-scale COVID-19 vaccination campaigns shows different long-term safety signals for the adenovirus-vector Johnson & Johnson (J&J/Janssen) shot versus the mR...
Yes — multi-dose vials and thimerosal remain part of the vaccine landscape in 2025, but their use has been sharply narrowed: thimerosal has been removed from most childhood vaccines since the late 199...
Tetanus is rare in the U.S.; since 2010 there have been fewer than 40 reported cases per year and most cases occur in adults not up to date on tetanus vaccines (CDC surveillance) . Childhood school‑ag...